Histamine H2 receptor · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Histamine H2 receptor shows approved-linked disease relevance led by gastroesophageal reflux disease. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P25021. Start with gastroesophageal reflux disease, then reuse UniProt P25021 as the stable protein anchor across project notes and exports.
Start with gastroesophageal reflux disease, then reuse UniProt P25021 as the stable protein anchor across project notes and exports.
Histamine H2 receptor shows approved-linked disease relevance led by gastroesophageal reflux disease. 5 more disease programs remain visible in the same review block. 6 linked drugs remain visible in the same block.
Start review with gastroesophageal reflux disease because it currently carries approved-linked support. Linked drugs include CIMETIDINE, FAMOTIDINE, LAFUTIDINE, NIZATIDINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyHistamine H2 receptor
Review this target as Histamine H2 receptor, mapped to UniProt P25021. Sequence length is 359 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Histamine H2 receptor as ChEMBL target CHEMBL1941, mapped to UniProt P25021. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Histamine H2 receptor is the right protein anchor across sources, using UniProt P25021 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why gastroesophageal reflux disease is currently framed as approved-linked support. It currently carries 6 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Histamine H2 receptor |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P25021 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Histamine H2 receptor |
| UniProt Accession | P25021 |
| Component Type | Protein |
| Sequence Length | 359 aa |
Histamine H2 receptor
Review this target as Histamine H2 receptor, mapped to UniProt P25021. Sequence length is 359 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Histamine H2 receptor shows approved-linked disease relevance led by gastroesophageal reflux disease. 5 more disease programs remain visible in the same review block.
Start review with gastroesophageal reflux disease because it currently carries approved-linked support. Linked drugs include CIMETIDINE, FAMOTIDINE, LAFUTIDINE, NIZATIDINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL194837 | 9.06 | IC50 | 0.87 | Preclinical |
| CHEMBL1627 | 8.77 | Ki | 1.7 | Preclinical |
| CHEMBL5276441 | 8.7 | Ki | 2.0 | Preclinical |
| CHEMBL4875600 | 8.69 | Ki | 2.042 | Preclinical |
| CHEMBL5207281 | 8.52 | Ki | 3.02 | Preclinical |
| CHEMBL5206565 | 8.48 | EC50 | 3.311 | Preclinical |
| CHEMBL4860528 | 8.35 | Ki | 4.467 | Preclinical |
| CHEMBL1090526 | 8.35 | Ki | 4.5 | Preclinical |
| CHEMBL5173079 | 8.32 | Ki | 4.786 | Preclinical |
| CHEMBL5178472 | 8.31 | EC50 | 4.898 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 315 | 220 | 5.5 |
| cell-based format | 97 | 115 | 6.2 |
| cell membrane format | 7 | 199 | 6.5 |
| assay format | 2 | 53 | 4.6 |
| tissue-based format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 50 | 105 | 6.7 |
| assay format | 16 | 4 | 5.9 |
| cell membrane format | 7 | 36 | 6.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 4 | 3 | 6.2 |
| single protein format | 1 | 0 | — |